Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review.
Adult
Aged
Breast
/ pathology
Breast Neoplasms
/ pathology
DNA Mutational Analysis
Female
Follow-Up Studies
Hemangiosarcoma
/ pathology
Humans
Immunohistochemistry
Middle Aged
Mutation
Neoplasm Grading
Neoplasms, Radiation-Induced
/ pathology
Oncogenes
/ genetics
Peptide Fragments
/ genetics
Prognosis
Proto-Oncogene Proteins p21(ras)
/ genetics
Radiotherapy
/ adverse effects
Skin Neoplasms
/ pathology
Telomerase
/ genetics
Vascular Malformations
/ pathology
atypical vascular lesions
breast
genes
haemangiosarcoma
neoplasms
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
09
12
2019
revised:
07
02
2020
accepted:
09
02
2020
pubmed:
12
2
2020
medline:
20
8
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
A wide range of post-radiotherapy (RT) vascular lesions can occur, ranging from benign lymphangiomatous papules of the skin (BLAPs), to atypical vascular lesions (AVLs) and post-RT angiosarcomas (ASs). The relationship between benign and malignant post-RT breast lesions and their prognostic features are still controversial. The aims of this study were to investigate the relationship between benign and malignant mammary post-RT vascular lesions and to define post-RT AS prognostic features. Seventy-four post-RT vascular lesion cases were obtained and stained with antibodies against CD34, CD31, D2-40, Ki67, and c-Myc. Mutational analysis was performed by deep sequencing for the following genes: KRAS, NRAS, HRAS, BRAF, PIK3CA, TP53, NOTCH1, PTEN, CDKN2A, EGFR, AKT1, CTNNB1, hTERT, and PTPRB. Post-RT AS cases were graded according to a previously reported breast AS grading system. AVL cases showed a low number of HRAS and hTERT mutations, whereas post-RT AS cases showed a high frequency of EGFR, TP53, HRAS and hTERT mutations. On follow-up, all BLAP and AVL patients were alive with no evidence of disease. Post-RT AS 5-year overall survival declined with the increase in grade, as follows: 85.7% for grade 1, 83.3% for grade 2, and 40.4% for grade 3. Our findings confirm that BLAP and AVL have a good prognosis, and that post-RT AS prognosis is strongly related to histological grading. On molecular analysis, AVL and post-RT AS shared HRAS and hTERT mutations, suggesting a relationship between the two lesions.
Substances chimiques
Peptide Fragments
0
GV1001 peptide
EC 2.7.7.-
Telomerase
EC 2.7.7.49
HRAS protein, human
EC 3.6.5.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-302Subventions
Organisme : University of Bologna
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Tavassoli A, Eusebi V. Sarcomas. In Silverberg SG eds. Tumors of the mammary gland. AFIP atlas of tumor pathology, series 4. Washington DC: American Registry of Pathology in collaboration with Armed Forces Institute of Pathology, 2009; 310-311.
Fraga-Guedes C, André S, Mastropasqua MG et al. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression. Breast Cancer Res. Treat. 2015; 151; 131-140.
Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am. J. Surg. Pathol. 2008; 32; 943-950.
Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am. J. Clin. Pathol. 1994; 102; 757-763.
Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am. J. Surg. Pathol. 2005; 29; 983-996.
Ginter PS, Mosquera JM, MacDonald TY, D’Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Hum. Pathol. 2014; 45; 709-716.
Ginter PS, McIntire PJ, Shin SJ. Vascular tumours of the breast: a comprehensive review with focus on diagnostic challenges encountered in the core biopsy setting. Pathology 2017; 49; 197-214.
Strobbe LJA, Peterse HL, van Tinteren H, Wijnmaalen A, Rutgers EJ. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome: an unforeseen sequela. Breast Cancer Res. Treat. 1998; 47; 101-109.
Bovée JVMG, Rosenberg AE. Vascular tumors. In Fletcher CDM, Bridge J, Hogendoorn P, MertensF eds, World Health Organization classification of tumors of soft tissue and bone. 4th edn. Lyon: International Agency for Research on Cancer (IARC), 2013; 156-158.
Donnell RM, Rosen PP, Lieberman PH et al. Angiosarcoma and other vascular tumors of the breast. Am. J. Surg. Pathol. 1981; 5; 629-642.
Rosen PP, Kimmel M. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988; 62; 2145-2151.
Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am. J. Surg. Pathol. 2008; 32; 1896-1904.
Hung J, Hiniker SM. Sporadic versus radiation-associated angiosarcoma: a comparative clinicopathologic and molecular analysis of 48 cases. Sarcoma 2013; 2013; 798403.
Murali R, Chandramohan R. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 2015; 6; 36041-36052.
Depla AL, Scharloo-Karels CH. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur. J. Cancer 2014; 50; 1779-1788.
Morandi L, Righi A, Maletta F et al. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. Endocr. Relat. Cancer 2017; 24; 107-117.
Gabusi A, Gissi DB, Tarsitano A et al. Intratumoral heterogeneity in recurrent metastatic squamous cell carcinoma of the oral cavity: new perspectives afforded by multiregion DNA sequencing and mtDNA analysis. J. Oral Maxillofac. Surg. 2019; 77; 440-455.
Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat. Methods 2010; 7; 248-249.